John from Luxembourg

Registered at the short selling broker Prime XBT, 3 minutes ago.

» Try Prime XBT you too
Don't show again

Aptose Biosciences, Inc. (APTO) shares information

Aptose Biosciences Inc


24h Change

-32.01 %

APTO

Live rate: Market closed

Stock data per Friday 11 Jun, 2021

APTO
NASDAQ CAPITAL MARKET
5.53
4.21
3.76
-1.77 (-32.01%)
US Market is closed

Live Stock price in graph for Aptose Biosciences Inc (APTO)

  • Latest Volume

    12,941,225 (730.61 %)

  • Volume prev. day

    1,558,033

  • Avg. daily volume

    1,169,953

  • Market cap

    334,447,277

  • P/E ratio

    n/a

  • Today high

    4.23 USD

  • Today low

    3.61 USD

  • 52 week high

    7.3 USD

  • 52 week low

    3.39 USD

  • YTD Change

    n/a

Quick links

 

Latest news about Aptose Biosciences Inc

Below you can find the most recent news posts about Aptose Biosciences Inc, primarily from US and UK based news sources.

Aptose Biosciences (APTO) Gets a Buy Rating from Alliance Global Partners

Saturday, 12 June 2021, 01:35:08
Alliance Global Partners analyst Matthew Cross maintained a Buy rating on Aptose Biosciences (APTO) today and set a price target of $12.00. The post Aptose Biosciences (APTO) Gets a Buy Rating from Alliance Global Partners appeared first on Smarter Analyst .
— Smarter Analyst


Aptose Biosciences Stock Tumbles As Luxeptinib Fails To Impress At EHA2021 Virtual Congress

Friday, 11 June 2021, 20:17:06
Aptose Biosciences Inc (NASDAQ: APTO ) highlighted data from its luxeptinib currently in two Phase 1 a/b trials – one in relapsed or refractory acute myeloid leukemia (AML) and another in relapsed or refractory B cell malignancies. In Relapsed or Refractory AML or High-Risk MDS trial, APTO-253 has been well-tolerated in the patients treated at 20, 40, 66, 100, and 150 mg/m2 over multiple cycles supporting continued Full story available on Benzinga.com
— Benzinga


Aptose Biosciences Stock Tumbles As Luxeptinib Fails To Impress At EHA2021 Virtual Congress

Friday, 11 June 2021, 16:17:00
Aptose Biosciences Inc (NASDAQ: APTO) highlighted data from its luxeptinib currently in two Phase 1 a/b trials – one in relapsed or
— Benzinga


Aptose tumbles on updated early-stage data luxeptinib in blood cancers

Friday, 11 June 2021, 15:17:24
No summary available.
— Seeking Alpha


Aptose Biosciences Announces Results of Annual Meeting of Shareholders

Tuesday, 1 June 2021, 22:30:00
SAN DIEGO and TORONTO, June 01, 2021 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Aptose or the Company) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced the voting results from the Companys annual and special meeting of shareholders held today, June 1, 2021 (the Meeting). A total of 72.83% of the issued and outstanding common shares of the Company were represented by shareholders present or represented by proxy at the Meeting.
— GlobeNewswire


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have APTO available or trade one of the many other CFD stocks they have.
Risk warning: 67.7% of retail investor accounts lose money when trading CFDs with Capital.